Acadia Pharmaceuticals Logo
US0042251084
603035
ACAD

Acadia Pharmaceuticals

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 27,31 (+66,73%). A mediana é € 29,99 (+83,09%).

Comprar
  25
Manter
  11
Vender
  1

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit

    A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » Mais em de.investing.com


  • Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference

    At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » Mais em de.investing.com


  • Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results

    Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » Mais em de.investing.com


  • FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin

    The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » Mais em de.investing.com


  • Acadia Pharmaceuticals insider sells nearly half of direct holdings

    James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026—about 46.6% of his direct holdings—at a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » Mais em finance.yahoo.com

Dados financeiros da empresa

No último trimestre, Acadia Pharmaceuticals registou receitas de € 302,19 mi e um ganho líquido de € 47,25 mi
(EUR) setembro de 2026
YoY
Receitas 302,19 mi 27,28%
Ganho bruto 271,21 mi 23,85%
Ganho líquido 47,25 mi 22,74%
EBITDA 71,02 mi 75,28%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 2,94 bi
Número de ações
172,83 mi
Máximo/mínimo de 52 semanas
€ 28,13 - € 14,41
Dividendos Não
Beta
0,89
PER (PE Ratio)
8,80
PEG (PEG Ratio)
0,24
P/VC (PB Ratio)
2,33
P/V (PS Ratio)
2,70

Perfil da empresa

A ACADIA Pharmaceuticals Inc., uma empresa biofarmacêutica, dedica-se ao desenvolvimento e à comercialização de fármacos de pequenas moléculas que respondem a necessidades médicas não satisfeitas em perturbações do sistema nervoso central. A empresa oferece o NUPLAZID (pimavanserina) para o tratamento de alucinações e delírios associados à psicose da doença de Parkinson. O seu pipeline inclui a pimavanserina, em desenvolvimento de fase 3 para o tratamento da psicose associada à doença de Alzheimer e dos sintomas negativos da esquizofrenia; a trofinetida, um novo análogo sintético, em desenvolvimento de fase 3 para o tratamento da síndrome de Rett; o ACP-044, um novo analgésico não opioide, administrado por via oral e pioneiro na sua classe, em desenvolvimento de fase 2 para o tratamento da dor aguda e crónica; e o ACP-319, um modulador alostérico positivo do recetor muscarínico, em desenvolvimento de fase 1 para o tratamento da esquizofrenia e da cognição na doença de Alzheimer. A ACADIA Pharmaceuticals Inc. foi fundada em 1993 e tem sede em San Diego, Califórnia.

Nome
Acadia Pharmaceuticals
CEO
Catherine E. Owen Adams
Sede San Diego, ca
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
27/05/2004
Colaboradores 797

Símbolos de ticker

Bolsa Símbolo
NASDAQ
ACAD
Frankfurt
DR6.F
Düsseldorf
DR6.DU
London
0A4W.L
SIX
DR6.SW
München
DR6.MU
🍪

Parqet  utiliza cookies. Saber mais